Free Trial

Genmab A/S (GMAB) Stock Forecast & Price Target

$28.17
+0.29 (+1.04%)
(As of 11:45 AM ET)

Genmab A/S - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 12 Wall Street analysts who have issued ratings for Genmab A/S in the last 12 months, the stock has a consensus rating of "Hold." Out of the 12 analysts, 3 have given a sell rating, 1 has given a hold rating, and 8 have given a buy rating for GMAB.

Consensus Price Target

$49.50
75.72% Upside
High Forecast$53.00
Average Forecast$49.50
Low Forecast$47.00

According to the 12 analysts' twelve-month price targets for Genmab A/S, the average price target is $49.50. The highest price target for GMAB is $53.00, while the lowest price target for GMAB is $47.00. The average price target represents a forecasted upside of 75.72% from the current price of $28.17.

TypeCurrent Forecast
7/26/23 to 7/25/24
1 Month Ago
6/26/23 to 6/25/24
3 Months Ago
4/27/23 to 4/26/24
1 Year Ago
7/26/22 to 7/26/23
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
8 Buy rating(s)
8 Buy rating(s)
4 Buy rating(s)
Hold
1 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
6 Hold rating(s)
Sell
3 Sell rating(s)
3 Sell rating(s)
3 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$49.50$49.25$48.50$40.25
Forecasted Upside75.72% Upside70.18% Upside58.87% Upside0.08% Upside
Get Genmab A/S Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter.

GMAB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GMAB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Genmab A/S Stock vs. The Competition

TypeGenmab A/SMedical CompaniesS&P 500
Consensus Rating Score
2.42
2.72
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside75.72% Upside3,274.42% Upside9.76% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/18/2024HC Wainwright
3 of 5 stars
 Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00+86.36%
7/15/2024Royal Bank of Canada
4 of 5 stars
A. Campbell
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSector Perform ➝ Outperform
6/27/2024BTIG Research
2 of 5 stars
 Boost TargetBuy ➝ Buy$46.00 ➝ $47.00+83.09%
6/4/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$50.00 ➝ $53.00+83.84%
3/26/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingUnderweight ➝ Underweight
2/23/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$46.00 ➝ $48.00+64.89%
1/22/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Sell
12/6/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy
11/10/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
11/8/2023DNB Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeSell ➝ Buy
10/18/2023BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageUnderperform
10/12/2023Nordea Equity Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
7/14/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
2/23/2023Danske
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
2/6/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform$33.00 ➝ $36.00-5.91%
1/3/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight3,450.00 ➝ 3,600.00
11/17/2022AlphaValue
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeReduce
11/15/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$43.00-0.23%
11/14/2022William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Phipps
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 12:09 PM ET.

GMAB Forecast - Frequently Asked Questions

What is Genmab A/S's forecast for 2024?

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Genmab A/S is $49.50, with a high forecast of $53.00 and a low forecast of $47.00.

Should I buy or sell Genmab A/S stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last twelve months. There are currently 3 sell ratings, 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMAB, but not buy additional shares or sell existing shares.

Does Genmab A/S's stock price have much upside?

According to analysts, Genmab A/S's stock has a predicted upside of 79.28% based on their 12-month stock forecasts.

Has Genmab A/S been upgraded by Wall Street analysts recently?

Over the previous 90 days, Genmab A/S's stock had 1 upgrade by analysts.

What analysts cover Genmab A/S?

Genmab A/S has been rated by research analysts at BTIG Research, HC Wainwright, Royal Bank of Canada, and Truist Financial in the past 90 days.

Do Wall Street analysts like Genmab A/S more than its competitors?

Analysts like Genmab A/S less than other "medical" companies. The consensus rating for Genmab A/S is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GMAB compares to other companies.


This page (NASDAQ:GMAB) was last updated on 7/25/2024 by MarketBeat.com Staff

From Our Partners